Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SID1903 FDC vs Loose Combination in Healthy Volunteers
NCT05236998Phase 1Completed
- Sponsor
- SK Chemicals
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by SK Chemicals. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration up to 72 hours and Maximum observed plasma concentration up to 72 hours. Started Nov 2021; status: completed.
02
Drugs
dapagliflozin + sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05236998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236998.